China · Delayed Price · Currency is CNY GemPharmatech Statistics
Total Valuation
GemPharmatech has a market cap or net worth of CNY 15.52 billion. The enterprise value is 14.60 billion.
| Market Cap | 15.52B |
| Enterprise Value | 14.60B |
Important Dates
The next confirmed earnings date is Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Jun 9, 2026 |
Share Statistics
GemPharmatech has 409.16 million shares outstanding. The number of shares has decreased by -2.46% in one year.
| Current Share Class | 409.16M |
| Shares Outstanding | 409.16M |
| Shares Change (YoY) | -2.46% |
| Shares Change (QoQ) | +9.12% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 12.49% |
| Float | 165.95M |
Valuation Ratios
The trailing PE ratio is 84.01 and the forward PE ratio is 77.43.
| PE Ratio | 84.01 |
| Forward PE | 77.43 |
| PS Ratio | 17.68 |
| PB Ratio | 6.85 |
| P/TBV Ratio | 7.06 |
| P/FCF Ratio | 67.38 |
| P/OCF Ratio | 51.78 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 51.95, with an EV/FCF ratio of 63.37.
| EV / Earnings | 79.98 |
| EV / Sales | 16.63 |
| EV / EBITDA | 51.95 |
| EV / EBIT | 77.81 |
| EV / FCF | 63.37 |
Financial Position
The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.10.
| Current Ratio | 3.63 |
| Quick Ratio | 3.37 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.83 |
| Debt / FCF | 1.01 |
| Interest Coverage | 29.84 |
Financial Efficiency
Return on equity (ROE) is 8.23% and return on invested capital (ROIC) is 11.57%.
| Return on Equity (ROE) | 8.23% |
| Return on Assets (ROA) | 4.16% |
| Return on Invested Capital (ROIC) | 11.57% |
| Return on Capital Employed (ROCE) | 7.92% |
| Weighted Average Cost of Capital (WACC) | 9.08% |
| Revenue Per Employee | 518,989 |
| Profits Per Employee | 107,888 |
| Employee Count | 1,692 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 4.04 |
Taxes
In the past 12 months, GemPharmatech has paid 29.20 million in taxes.
| Income Tax | 29.20M |
| Effective Tax Rate | 13.79% |
Stock Price Statistics
The stock price has increased by +114.84% in the last 52 weeks. The beta is 0.90, so GemPharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +114.84% |
| 50-Day Moving Average | 32.69 |
| 200-Day Moving Average | 21.96 |
| Relative Strength Index (RSI) | 61.74 |
| Average Volume (20 Days) | 10,762,564 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemPharmatech had revenue of CNY 878.13 million and earned 182.55 million in profits. Earnings per share was 0.45.
| Revenue | 878.13M |
| Gross Profit | 558.09M |
| Operating Income | 187.64M |
| Pretax Income | 211.75M |
| Net Income | 182.55M |
| EBITDA | 264.12M |
| EBIT | 187.64M |
| Earnings Per Share (EPS) | 0.45 |
Balance Sheet
The company has 1.16 billion in cash and 233.60 million in debt, with a net cash position of 922.48 million or 2.25 per share.
| Cash & Cash Equivalents | 1.16B |
| Total Debt | 233.60M |
| Net Cash | 922.48M |
| Net Cash Per Share | 2.25 |
| Equity (Book Value) | 2.27B |
| Book Value Per Share | 5.54 |
| Working Capital | 1.23B |
Cash Flow
In the last 12 months, operating cash flow was 299.80 million and capital expenditures -69.40 million, giving a free cash flow of 230.40 million.
| Operating Cash Flow | 299.80M |
| Capital Expenditures | -69.40M |
| Depreciation & Amortization | 76.48M |
| Net Borrowing | -121.38M |
| Free Cash Flow | 230.40M |
| FCF Per Share | 0.56 |
Margins
Gross margin is 63.55%, with operating and profit margins of 21.37% and 20.79%.
| Gross Margin | 63.55% |
| Operating Margin | 21.37% |
| Pretax Margin | 24.11% |
| Profit Margin | 20.79% |
| EBITDA Margin | 30.08% |
| EBIT Margin | 21.37% |
| FCF Margin | 26.24% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 0.58%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 0.58% |
| Dividend Growth (YoY) | 57.14% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 75.30% |
| FCF Payout Ratio | 39.07% |
| Buyback Yield | 2.46% |
| Shareholder Yield | 3.04% |
| Earnings Yield | 1.18% |
| FCF Yield | 1.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GemPharmatech has an Altman Z-Score of 8.82 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.82 |
| Piotroski F-Score | 7 |